Lithium: a potential therapeutic strategy in obsessive–compulsive disorder by targeting the canonical WNT/β pathway
Abstract Obsessive–compulsive disorder (OCD) is a neuropsychiatric disorder characterized b–y recurrent and distinctive obsessions and/or compulsions. The etiologies remain unclear. Recent findings have shown that oxidative stress, inflammation, and the glutamatergic pathway play key roles in the ca...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Publishing Group
2021-04-01
|
| Series: | Translational Psychiatry |
| Online Access: | https://doi.org/10.1038/s41398-021-01329-3 |
| _version_ | 1818730072640585728 |
|---|---|
| author | Alexandre Vallée Jean-Noël Vallée Yves Lecarpentier |
| author_facet | Alexandre Vallée Jean-Noël Vallée Yves Lecarpentier |
| author_sort | Alexandre Vallée |
| collection | DOAJ |
| description | Abstract Obsessive–compulsive disorder (OCD) is a neuropsychiatric disorder characterized b–y recurrent and distinctive obsessions and/or compulsions. The etiologies remain unclear. Recent findings have shown that oxidative stress, inflammation, and the glutamatergic pathway play key roles in the causes of OCD. However, first-line therapies include cognitive–behavioral therapy but only 40% of the patients respond to this first-line therapy. Research for a new treatment is mandatory. This review focuses on the potential effects of lithium, as a potential therapeutic strategy, on OCD and some of the presumed mechanisms by which lithium provides its benefit properties. Lithium medication downregulates GSK-3β, the main inhibitor of the WNT/β-catenin pathway. The activation of the WNT/β-catenin could be associated with the control of oxidative stress, inflammation, and glutamatergic pathway. Future prospective clinical trials could focus on lithium and its different and multiple interactions in OCD. |
| first_indexed | 2024-12-17T22:55:58Z |
| format | Article |
| id | doaj.art-5c3923f44baf41dfb6b211c67b95052d |
| institution | Directory Open Access Journal |
| issn | 2158-3188 |
| language | English |
| last_indexed | 2024-12-17T22:55:58Z |
| publishDate | 2021-04-01 |
| publisher | Nature Publishing Group |
| record_format | Article |
| series | Translational Psychiatry |
| spelling | doaj.art-5c3923f44baf41dfb6b211c67b95052d2022-12-21T21:29:32ZengNature Publishing GroupTranslational Psychiatry2158-31882021-04-011111910.1038/s41398-021-01329-3Lithium: a potential therapeutic strategy in obsessive–compulsive disorder by targeting the canonical WNT/β pathwayAlexandre Vallée0Jean-Noël Vallée1Yves Lecarpentier2Department of Clinical Research and Innovation (DRCI), Foch HospitalCentre Hospitalier Universitaire (CHU) Amiens Picardie, Université Picardie Jules VerneCentre de Recherche Clinique, Grand Hôpital de l’Est Francilien (GHEF)Abstract Obsessive–compulsive disorder (OCD) is a neuropsychiatric disorder characterized b–y recurrent and distinctive obsessions and/or compulsions. The etiologies remain unclear. Recent findings have shown that oxidative stress, inflammation, and the glutamatergic pathway play key roles in the causes of OCD. However, first-line therapies include cognitive–behavioral therapy but only 40% of the patients respond to this first-line therapy. Research for a new treatment is mandatory. This review focuses on the potential effects of lithium, as a potential therapeutic strategy, on OCD and some of the presumed mechanisms by which lithium provides its benefit properties. Lithium medication downregulates GSK-3β, the main inhibitor of the WNT/β-catenin pathway. The activation of the WNT/β-catenin could be associated with the control of oxidative stress, inflammation, and glutamatergic pathway. Future prospective clinical trials could focus on lithium and its different and multiple interactions in OCD.https://doi.org/10.1038/s41398-021-01329-3 |
| spellingShingle | Alexandre Vallée Jean-Noël Vallée Yves Lecarpentier Lithium: a potential therapeutic strategy in obsessive–compulsive disorder by targeting the canonical WNT/β pathway Translational Psychiatry |
| title | Lithium: a potential therapeutic strategy in obsessive–compulsive disorder by targeting the canonical WNT/β pathway |
| title_full | Lithium: a potential therapeutic strategy in obsessive–compulsive disorder by targeting the canonical WNT/β pathway |
| title_fullStr | Lithium: a potential therapeutic strategy in obsessive–compulsive disorder by targeting the canonical WNT/β pathway |
| title_full_unstemmed | Lithium: a potential therapeutic strategy in obsessive–compulsive disorder by targeting the canonical WNT/β pathway |
| title_short | Lithium: a potential therapeutic strategy in obsessive–compulsive disorder by targeting the canonical WNT/β pathway |
| title_sort | lithium a potential therapeutic strategy in obsessive compulsive disorder by targeting the canonical wnt β pathway |
| url | https://doi.org/10.1038/s41398-021-01329-3 |
| work_keys_str_mv | AT alexandrevallee lithiumapotentialtherapeuticstrategyinobsessivecompulsivedisorderbytargetingthecanonicalwntbpathway AT jeannoelvallee lithiumapotentialtherapeuticstrategyinobsessivecompulsivedisorderbytargetingthecanonicalwntbpathway AT yveslecarpentier lithiumapotentialtherapeuticstrategyinobsessivecompulsivedisorderbytargetingthecanonicalwntbpathway |